Brief: Xspray Q2 Revenue SEK 0
07/08/2024 07:00
Aug 07 (Reuters) - Xspray Q2 pretax profit SEK -53.62 million. * Q2 adjusted free cash flow SEK -64.181 million * Q2 adjusted EPS SEK -1.64
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003